BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00299390
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 261
- Registration Number
- NCT00296855
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 190
- Registration Number
- NCT00293059
- Locations
- 🇺🇸
Clinical Physiology Associates, Inc., Fort Myers, Florida, United States
🇺🇸South Carolina Clinical Research Center, Columbia, South Carolina, United States
🇺🇸Advanced Research Associates, Corpus Christi, Texas, United States
Menorrhagia Study in Women With Treatment-resistant Menorrhagia
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00288691
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 82
- Registration Number
- NCT00288249
Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1326
- Registration Number
- NCT00280657
Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1166
- Registration Number
- NCT00266032
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 53
- Registration Number
- NCT00259129
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 106
- Registration Number
- NCT00250640
Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT00246688
© Copyright 2024. All Rights Reserved by MedPath